Atreca, Inc. (BCEL)

NASDAQ: BCEL · IEX Real-Time Price · USD
1.04
0.00 (0.00%)
Dec 2, 2022 4:00 PM EST - Market closed
Market Cap 40.63M
Revenue (ttm) n/a
Net Income (ttm) -105.33M
Shares Out 38.72M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 203,563
Open 1.04
Previous Close 1.04
Day's Range 0.99 - 1.06
52-Week Range 0.99 - 5.36
Beta 0.67
Analysts Buy
Price Target 12.24 (+1,076.9%)
Earnings Date Nov 11, 2022

About BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine... [Read more]

Industry Biotechnology
IPO Date Jun 20, 2019
CEO John Orwin
Employees 91
Stock Exchange NASDAQ
Ticker Symbol BCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for BCEL stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 1,076.92% from the latest price.

Price Target
$12.24
(1,076.92% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on de...

3 weeks ago - GlobeNewsWire

Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

3 weeks ago - GlobeNewsWire

Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

1 month ago - GlobeNewsWire

Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

3 months ago - GlobeNewsWire

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Busi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

5 months ago - Business Wire

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

5 months ago - GlobeNewsWire

Atreca Announces Corporate Reorganization to Extend Cash Runway

Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets

6 months ago - GlobeNewsWire

Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique disc...

6 months ago - GlobeNewsWire

Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targ...

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique disc...

6 months ago - GlobeNewsWire

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...

7 months ago - GlobeNewsWire

Atreca Announces Expansion of Preclinical Pipeline

Atreca Announces Licensing Agreement with Zymeworks

7 months ago - GlobeNewsWire

Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022

SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...

8 months ago - GlobeNewsWire

Has Atreca, Inc. (BCEL) Outpaced Other Medical Stocks This Year?

Here is how Atreca, Inc. (BCEL) and Indivior PLC (INVVY) have performed compared to their sector so far this year.

8 months ago - Zacks Investment Research

Can Atreca, Inc. (BCEL) Climb 310% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 310.2% upside potential for Atreca, Inc. (BCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...

8 months ago - Zacks Investment Research

Atreca to Participate in Cowen 42nd Annual Healthcare Conference

SAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...

8 months ago - GlobeNewsWire

Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update

Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial

9 months ago - GlobeNewsWire

Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022

SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

9 months ago - GlobeNewsWire

Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should Know

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

10 months ago - GlobeNewsWire

Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

1 year ago - GlobeNewsWire

Atreca Ink Licensing Pact With Gates Research On Malaria Antibody

Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria.  MAM01/ATRC-501 is a monoclonal an...

1 year ago - Benzinga

Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

1 year ago - GlobeNewsWire

Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

1 year ago - GlobeNewsWire

Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101

Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET

1 year ago - GlobeNewsWire

Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors

SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique disc...

1 year ago - GlobeNewsWire